[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593278":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Helene Masse, M.D","CONTACT","+33 2 53 48 28 57","helene.masse@chu-nantes.fr",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Alexandra Poinas, PhD","alexandra.poinas@chu-nantes.fr",[18],{"facility":19,"status":20,"city":21,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"CHU Nantes - Ophthalmology Department","RECRUITING","Nantes","44000","France","FR",{"type":26,"coordinates":27},"Point",[28,29],-1.55336,47.21725,{"lat":29,"lon":28},[32],{"name":33,"role":11,"phone":34,"phoneExt":7,"email":16},"Alexandra Poinas","+33 2 40 08 33 33",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100593278","ethical-issues-of-using-gene-therapy-in-the-treatment-of-amd-100593278",false,"NCT07004361","Ethical Issues of Using Gene Therapy in the Treatment of AMD","Ethical Issues of Using Gene Therapy in the Treatment of AMD (Age-related Macular Degeneration)","Inclusion Criteria:\n\n* Patients with exsudative AMD, male female \\>18 years Patients for whom the doctor could consider gene therapy.\n\nExclusion Criteria:\n\nPatients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.","ALL","18 Years",{"count":47,"type":48},30,"ESTIMATED","OBSERVATIONAL","The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence\u002Fnon-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.",[52],"Exudative Age-related Macular Degeneration",[54,55],"ethical","Age-related Macular Degeneration","2026-06-23",{"date":58,"type":59},"2026-06-24","ACTUAL",{"date":61,"type":59},"2025-07-01",{"date":63,"type":48},"2026-12",{"name":5,"class":6},1]